Cocrystal Pharma, Inc. (COCP) |
|
2.71 -0.11 (-3.9%)
|
01-27 16:00 |
|
Open: |
2.76 |
Pre. Close: |
2.82 |
|
High:
|
2.88 |
Low:
|
2.71 |
|
Volume:
|
58,763 |
Market Cap:
|
22(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:29 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.59 One year: 4.2 |
| Support: |
Support1: 2.25 Support2: 1.74 |
| Resistance: |
Resistance1: 3.07 Resistance2: 3.59 |
| Pivot: |
2.38  |
| Moving Average: |
MA(5): 2.73 MA(20): 2.28
MA(100): 2.77 MA(250): 4.38 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 78.8 %D(3): 86.5 |
| RSI: |
RSI(14): 59.6 |
| 52-week: |
High: 7.55 Low: 0.37 |
| Average Vol(K): |
3-Month: 50 (K) 10-Days: 97 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COCP ] has closed below upper band by 22.1%. Bollinger Bands are 11.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.88 - 2.9 |
2.9 - 2.91 |
|
Low:
|
2.67 - 2.69 |
2.69 - 2.71 |
|
Close:
|
2.68 - 2.71 |
2.71 - 2.73 |
|
Company Description |
|
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington. |
Headline News |
Thu, 26 Jan 2023
2023-01-26 | NDAQ:COCP | Press Release | Cocrystal Pharma Inc. - Stockhouse
Wed, 25 Jan 2023
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 ... - Investing.com UK
Sun, 22 Jan 2023
Cadrenal Therapeutics Stock (NASDAQ:CVKD), Quotes and News ... - Benzinga
Tue, 17 Jan 2023
Influencers spreading sexual health misinformation: Study - RACGP
Fri, 06 Jan 2023
Where Will Cocrystal Pharma Inc (COCP) Stock Go Next After It Is Higher By 14.13% in a Week? - InvestorsObserver
Thu, 17 Nov 2022
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
6 (M) |
|
% Held by Insiders
|
13.1 (%) |
|
% Held by Institutions
|
20.5 (%) |
|
Shares Short
|
20 (K) |
|
Shares Short P.Month
|
13 (K) |
Stock Financials |
|
EPS
|
-0.17 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-16.9 |
|
Return on Equity (ttm)
|
-60.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.08 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-16.43 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.5 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-01-23 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
